Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
2(15%)
Results Posted
60%(6 trials)

Phase Distribution

Ph phase_1
4
31%
Ph phase_2
8
62%
Ph phase_3
1
8%

Phase Distribution

4

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(10)
Other(1)

Detailed Status

Completed10
Active, not recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (30.8%)
Phase 28 (61.5%)
Phase 31 (7.7%)

Trials by Status

completed1077%
active_not_recruiting18%
recruiting18%
unknown18%

Recent Activity

2 active trials
Showing 5 of 13
completedphase_2

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

NCT05513560
completedphase_2

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
active_not_recruitingphase_2

Ibudilast for Treating Alcohol Use Disorder

NCT05414240
completedphase_2

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435
completedphase_2

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05513560Phase 2

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Completed
NCT03341078Phase 2

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Completed
NCT05414240Phase 2

Ibudilast for Treating Alcohol Use Disorder

Active Not Recruiting
NCT03594435Phase 2

Ibudilast for the Treatment of Alcohol Use Disorder

Completed
NCT04429555Phase 2

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Completed
NCT02714036Phase 1

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

Completed
NCT04631471Phase 3

Regeneration in Cervical Degenerative Myelopathy

Recruiting
NCT03489850Phase 2

Ibudilast and Withdrawal-Related Dysphoria

Completed
NCT01982942Phase 2

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Completed
NCT01860807Phase 2

Trial of Ibudilast for Methamphetamine Dependence

Completed
NCT02025998Phase 1

Development of Ibudilast for Alcohol Use Disorder

Completed
NCT01389193Phase 1

Ibudilast in the Treatment of Patients With Chronic Migraine.

Completed
NCT01317992Phase 1

Ibudilast in the Treatment of Medication Overuse Headache

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13